NASDAQ:FATE
Fate Therapeutics, Inc.
- Stock
locale
United States
market
STOCKSindustry
Biotechnologywebsite
www.fatetherapeutics.comipo date
Oct 01, 2013
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic...Show More
Earnings
Earnings Release in 10 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus